

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number  
WO 03/054517 A2

(51) International Patent Classification<sup>7</sup>: G01N (74) Agents: MANDRAGOURAS, Amy, E. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(21) International Application Number: PCT/US02/41061

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 19 December 2002 (19.12.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/341,938 19 December 2001 (19.12.2001) US  
60/393,038 28 June 2002 (28.06.2002) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): BIOGEN, INC. [US/US]; Fourteen Cambridge Center, Cambridge, MA 02142 (US).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and  
(75) Inventors/Applicants (for US only): VASILYEVA, Elena [RU/US]; 122 Babcock Street, Apartment 3, Brookline, MA 02446 (US). BROWN, Francine [US/US]; 2 Dodge Road, Westford, MA 01886 (US). KRETSCHMER, Matthias [US/US]; 12 Viles Street, Weston, MA 02493 (US). BOVE, Peter [US/US]; 4 East Terrace, Burlington, VT 05405 (US).

WO 03/054517 A2

(54) Title: METHODS FOR DETECTING HALF-ANTIBODIES USING CHIP-BASED GEL ELECTROPHORESIS

(57) Abstract: The invention provides a method of using chip-based gel electrophoresis to determine the presence of polypeptides with selected disulfide linkage patterns, for example, completely formed tetrameric antibodies as compared to incompletely formed heterodimeric half-antibodies. The invention further features a kit, comprising a chip, and instructions for conducting the foregoing method. The methods and kits of the invention are amendable to high throughput applications for the monitoring of production and quality control of recombinant therapeutic antibodies.

## METHODS FOR DETECTING HALF-ANTIBODIES USING CHIP-BASED GEL ELECTROPHORESIS

### Related Information

5 The application claims priority to U.S. provisional patent application number 60/393,038, filed on June 28, 2002, and U.S. provisional patent application number 60/341,938, filed on December 19, 2001, the entire contents both of which are hereby incorporated by reference.

10 The contents of any patents, patent applications, and references cited throughout this specification are hereby incorporated by reference in their entireties.

### Background of the Invention

15 The immune response is a mechanism by which the body defends itself against foreign substances that invade it, causing infection or disease. This mechanism is based on the identification and binding of these foreign substances by antibodies. Once a substance is bound by an antibody, the substance is targeted for destruction.

20 Antibodies are composed of four polypeptides, two light chains and two heavy chains (L:H:H:L). Most antibodies contain disulfide bonds between the four polypeptide chains. Occasionally, so called half-antibodies occur, in which the disulfide bonds between the heavy chain polypeptides are not formed.

25 For some antibodies, such as the IgG4 class, 25-30% of IgG4 antibodies are produced as half-antibodies comprising a heavy and light chain, regardless of whether the molecules are produced recombinantly or naturally. For other antibody isotypes and sub-isotypes, half-antibody formation has been associated with aberrant protein forms. For example, half-antibody formation may be due to the structure of the hinge region, as in IgG4 antibodies, or with deletions in the heavy chain constant domains, as with antibodies produced by certain myelomas.

30 Half-antibodies are not associated with a distinct clinical syndrome, however, they have been identified in the serum and urine of patients with a variety of diseases such as multiple myeloma, plasma cell leukemia, and plasmacytoma. Half-antibodies, to some degree, are also produced by murine hybridomas and myelomas, and a byproduct of recombinant antibody production in both animal and bacterial cells. Many of these antibodies are potentially biologically less active when incomplete, and therefore have the potential to dilute the therapeutic effectiveness of a pharmaceutical preparation containing such half-antibodies. Accordingly, the ability to detect such molecules is desirable.

The typical method of determining the amount of half-antibodies in a sample, is by standard gel electrophoresis. This method is slow and error prone.

Accordingly, a need exists for an improved method for determining the presence of half-antibodies (as compared to completely formed antibodies), for monitoring and 5 improving the quality control of antibody-based pharmaceuticals.

### Summary of the Invention

The invention solves the foregoing problems of standard gel electrophoresis by providing improved methods for detecting the presence of a selected disulfide-linked 10 polypeptide, for example, a half-antibody, as compared to a completely formed antibody. Typically, a completely formed antibody is a tetramer comprising two heavy chain polypeptides and two light chain polypeptides linked by disulfide bonds (L:H:H:L), whereas a half-antibody is a disulfide-linked light chain and heavy chain polypeptide (L:H) incompletely disulfide-linked or entirely unlinked to a corresponding 15 light chain and heavy chain polypeptide (H:L) (Figure 11). Other exemplary molecules amenable to the methods described herein include any multimeric polypeptides having one or more disulfide bonds. The method of the invention is especially useful for determining the nature of disulfide linked multimeric polypeptides destined for use in human therapeutic applications, as well as, diagnostic and research applications.

20 The method employs chip-based gel electrophoresis which can readily, and rapidly, identify incompletely formed polypeptides, *i.e.*, polypeptides having an incomplete number of disulfide linkage(s), for example, as compared to polypeptides having the desired number or placement of disulfide linkages. Two prominent examples include; antibodies, *e.g.*, IgG4 antibodies which comprise four polypeptide chains held 25 together by disulfide bonds, and multichain ligands, for example, growth factors.

Accordingly, the invention has several advantages which include, but are not limited to, the following:

30 -a detection method of improved fidelity that can rapidly determine the amount of a selected disulfide-linked polypeptide, for example, a completely formed antibody as compared to an incompletely linked polypeptide, for example, a half-antibody, or undesired impurities;

35 - a method for monitoring the quality control over the production, for example, recombinant production, of a polypeptide multimer (*e.g.*, an antibody) for therapeutic use in, for example, a human subject; and

- a kit which can be used with commercially available chips for conducting the methods of the invention.

Accordingly, in one aspect, the invention provides a method for detecting the presence of a IgG4 polypeptide having a selected disulfide linkage pattern in a sample,

in which a sample containing a polypeptide having a selected disulfide linkage pattern is loaded onto a chip containing a channel having a separation medium effective to act as an obstacle to the migration of the polypeptide having a selected disulfide linkage pattern, and at least two electrodes disposed within the channel to induce an electric field. An electric field is applied across the separation medium of the chip, whereby a separation of the IgG4 polypeptide having a selected disulfide linkage pattern as compared to a IgG4 polypeptide not having the selected disulfide linkage pattern is achieved. The presence of the IgG4 polypeptide having a selected disulfide linkage pattern is determined, for example, the amount (e.g., percentage) of a completely formed 10 (i.e., disulfide linked) antibody, half-antibody, or ratio thereof.

In a related aspect, the invention provides a method for detecting the presence of a polypeptide having a selected disulfide linkage pattern in a sample consisting of a mixture of polypeptide multimers having two or more polypeptide chains and containing, at least one disulfide linkage between the polypeptide chains. According to 15 the method, a sample containing the mixture of polypeptide multimers is loaded onto a chip containing a channel having a separation medium effective to act as an obstacle to the migration of the polypeptide having a selected disulfide linkage pattern, and at least two electrodes disposed within the channel to induce an electric field. An electric field is applied across the separation medium of the chip whereby a separation of the 20 polypeptide having a selected disulfide linkage pattern as compared to a polypeptide not having the selected disulfide linkage pattern is achieved. The presence of the polypeptide having a selected disulfide linkage pattern is detected. Such a peptide being, for example, a completely formed antibody or half-antibody.

In a specific embodiment, the method is used to detect the presence of an IgG4 25 half-antibody, an IgG4 antibody, polypeptide impurities, or the ratio of any of the foregoing antibodies or polypeptides.

In a related embodiment, the antibody is a monoclonal antibody, for example, a humanized antibody, in particular, an anti-integrin antibody (e.g., an anti-alpha-4-beta-1 (VLA-4) antibody, anti-alpha-4-beta 7 (VLA-7) antibody, or an antibody that binds both 30 VLA-4 and VLA-7, e.g., natalizumab).

In another embodiment, the sample comprises a polypeptide (e.g., a polypeptide with a disulfide linkage, e.g., an antibody of ligand) at a concentration of about 1 ug/ml to about 500 ug/ml (including any range of polypeptide concentration therein, e.g., 1-10 ug/ml; 10-100 ug/ml; 100-500 ug/ml; 500-1000 ug/ml; and 1000-5000 ug/ml, as well as 35 any overlapping range or narrower range of the foregoing polypeptide concentration ranges).

In another embodiment, the method detects a polypeptide that is a ligand having a selected disulfide linkage pattern, for example, completely formed as compared to incompletely formed.

5 In another embodiment, the above methods are suitable for detecting a selected disulfide linkage in a polypeptide that is produced recombinantly.

In another embodiment, the above methods are suitable for detecting a selected disulfide linkage in a polypeptide that is produced recombinantly.

10 In a related embodiment, the method is suitable for detecting polypeptide impurities in the presence of the foregoing ligand, antibody, half-antibody, or disulfide linked polypeptide.

In a related embodiment, the method detects a selected disulfide linkage in polypeptide that is isolated from the growth medium of a cell culture.

In a related embodiment, the separation medium used in the above method is a gel polymer, for example, a non-reducing gel polymer.

15 In a related embodiment, the migration of the polypeptide in the separation medium is detected using a fluorescence detector.

In a related embodiment, the polypeptides are separated according to their molecular weights.

20 In a related embodiment, the separation mechanism comprises isoelectric focusing, in which the molecules are separated based on their isoelectric point.

In another embodiment, the chip used in the separation method comprises a precast gel polymer.

25 In yet another embodiment, the invention provides a kit for detecting the presence of a polypeptide having a selected disulfide linkage pattern. The kit contains a chip, and instructions for carrying out the method described herein for determining the presence of a polypeptide with a selected disulfide pattern, for example, an antibody, half-antibody, or polypeptide impurity, or ratio of any of the foregoing antibodies or polypeptides.

30 In a still another embodiment, the invention provides a kit for determining the purity of a therapeutic polypeptide having a selected disulfide-linkage pattern. The kit contains a chip and instructions for carrying out the method for determining the amount of polypeptide with a selected disulfide linkage pattern, for example, an antibody, half-antibody, or polypeptide impurity, or ratio of any of the foregoing antibodies or polypeptides.

35 In a related embodiment, the invention features a kit for determining the presence or purity of a polypeptide with a selected disulfide-linkage pattern consisting of a chip, instructions for carrying out the assay for determining the amount of polypeptide with a selected disulfide-linkage pattern, and one or more of the following

components such as, separation medium, non-reducing buffer, protein dye, formulation buffer, or a means for inducing an electric field through a separation medium.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

5

**Brief Description of the Drawings**

**Figure 1** depicts a chromatograph showing the sizing accuracy (by migration time) of the method on an intact antibody (anti-integrin antibody) and corresponding half-antibody, as a function of sample concentration.

10

**Figure 2** depicts chromatographs showing increasing amounts (panels A-D) of an antibody (anti-integrin antibody), as compared to a control, to determine the linear dynamic range of the assay.

15

**Figure 3** depicts the linearity of the method by plotting the relative concentration (calculated by determination of fluorescence by comparison to a marker of known concentration running with the sample) versus the actual sample concentration (determined by A<sub>280</sub> readings) of an antibody (anti-integrin antibody), using the concentration range of 100 µg/ml to 5000 µg/ml.

20

**Figure 4** depicts the linearity of the method by plotting the relative concentration versus the sample concentration of an antibody (anti-integrin antibody), using the concentration range of 100 µg/ml to 2000 µg/ml.

25

**Figure 5** depicts the linearity of the method by plotting the relative concentration versus the sample concentration of half-antibodies using the concentration range of 100 µg/ml to 5000 µg/ml.

30

**Figure 6** depicts the linearity of the method by plotting the relative concentration versus the sample concentration of half-antibodies using the concentration range of 100 µg/ml to 2000 µg/ml.

35

**Figure 7** depicts the correlation between the relative and absolute concentration of sample determined by software analysis and the real sample concentration based on absorbance readings.

**Figure 8** depicts a graph showing the % of half-antibody at sample protein amounts ranging from 0.1 µg to 0.5 µg.

**Figure 9** depicts a graph showing the % of half-antibody at sample protein concentrations ranging from 10 µg/ml to 4900 µg/ml used to determine optimum sample concentration.

5      **Figure 10** depicts a chromatograph used to detect the lowest detectable concentration of half-antibody using the assay.

**Figure 11** depicts the structure of an antibody with intrachain and interchain disulfide linkages indicated. Typically, IgG4 intrachain disulfide linkages occur  
10      between light chain residues 23 and 92; 138 and 198; and between heavy chain residues 22 and 96; 145 and 201; 262 and 322; and 368 and 426. IgG4 inter-heavy chain disulfide linkages typically occur at residues 227 and 230.

15      **Figure 12** depicts a histogram of an exemplary sample having known concentrations of “impurities” as represented by marker proteins for determining the level of detection of impurities using the chip-based gel electrophoresis method (see also Table 7 and text).

**Figure 13** depicts a digital image of SDS-PAGE analysis of exemplary test samples and the contaminants that can be detected using the chip-based gel  
20      electrophoresis method in a recombinant antibody preparation. The arrows pointing to the right indicate known contaminant protein bands (sample/lane 1 contains trypsin inhibitor, sample/lane 2 contains ovalbumin, sample/lane 3 contains  $\beta$ -galactosidase, and sample/lane 4 contains a control standard). The arrows pointing to the left indicate contaminant proteins from the recombinant sample and “HC” and “LC” indicate,  
25      respectively, the heavy and light chains of the recombinant antibody (*i.e.*, natalizumab).

**Figure 14** depicts chromatographs using the chip-based method of representative samples containing contaminant proteins previously examined by SDS-PAGE (Figure 13). Panels appearing from top to bottom correspond to lanes 1-4 of the  
30      gel image shown in Figure 13. In each case, the marker protein (*i.e.*, trypsin inhibitor, top panel; ovalbumin, second panel down;  $\beta$ -galactosidase, third panel down) is easily detected as a peak (see arrows) which does not occur in the control standard (bottom panel).

### Detailed Description of the Invention

In order to provide a clear understanding of the specification and claims, the following definitions are conveniently provided below.

#### 5 *Definitions*

As used herein the term a “ polypeptide having a selected disulfide linkage” includes a half-antibody where the selected disulfide linkage occurs between the light chain polypeptide and heavy chain polypeptide and not between the heavy chain polypeptides.

10 The term “chip” includes any solid substrate having a means for containing a separation medium that can have an electric field applied across the medium such that it can be used to separate macromolecules, *e.g.*, multimeric polypeptides, such as antibodies and half-antibodies.

15 The term “separation medium” includes any compound, for example, polymer gel, that can be used to differentially separate macromolecules, *e.g.*, multimeric polypeptides, such as antibodies and half-antibodies and is generally understood to comprise an appropriate buffer solution.

20 The term “half-antibody” includes antibodies in which, the inter-heavy chain disulfide bond(s) are absent, such that a single light chain polypeptide and a single heavy chain polypeptide form unconnected to a corresponding single light chain polypeptide and a single heavy chain polypeptide.

The term “IgG4 class” includes a subclass of IgG immunoglobulins that are produced during a secondary immune response and are most commonly found in the blood. These IgG antibodies typically contain the  $\gamma 4$  heavy chain.

25 The term “non-reducing” refers to conditions under which disulfide-bonds (*e.g.*, disulfide linkage(s) are preserved. Specifically, conditions under which disulfide bonds remain intact and are not converted to free sulfhydryls.

30 The term “isoelectric focusing” includes methods in which macromolecules will migrate and focus in a pH gradient, established by applying an electric charge to a solution of carrier ampholytes, according to their isoelectric point (pI).

The term “integrin” includes any polypeptide representative of the large family of transmembrane proteins, so named, which are involved in the adhesion of cells to the extracellular matrix. Accordingly, the term an “anti-integrin antibody” is an antibody that binds to such a molecule. Examples of anti-integrin antibodies include such antibodies as anti-alpha-4-beta-1 (VLA-4) antibodies, anti-alpha-4-beta 7 (VLA-7) antibodies, and antibodies that bind both VLA-4 and VLA-7, *e.g.*, natalizumab (see, for example, U.S. Patent No. 6,033,665, and U.S. Patent No. 5,840,299.

***Detailed Description***

A method has been developed to detect the presence of a polypeptide having a selected disulfide-linkage, for example an antibody, using chip-based gel electrophoresis. The method is especially well suited for detecting the presence, 5 absence, or relative amounts (ratios) of completely formed antibody (which is a disulfide-linked tetramer), for example an IgG4 antibody, as compared to an incompletely formed antibody, for example, a half-antibody, lacking inter-heavy chain disulfide linkage(s) (which is a disulfide-linked heterodimer). In addition, the method can be used to detect the presence of impurities in a sample, *e.g.*, polypeptide impurities. 10 The method typically uses an Agilent 2100 Bioanalyzer in combination with the Protein 200 (or 200 Plus) LabChip kit and Protein 200 assay software (available from Agilent Technologies), although similarly conformed hardware, reagents, and software may be used.

As proof of principle, the method of the invention described herein uses test 15 samples obtained during the production of a recombinant antibody for therapeutic use, specifically, an anti-integrin antibody, although it is understood that the method can be equally applied to any antibody sample whether naturally-derived (*e.g.*, from serum), produced by a cell line (*e.g.*, a hybridoma), or produced in a transgenic organism.

The method offers several advantages over current SDS-PAGE method, for 20 example, chip-based gel electrophoresis is highly automated, and is easy to use. In contrast to the conventional SDS-PAGE, no additional manual staining or destaining steps are required. In addition, automation allows for near real time analysis of a polypeptide product at different stages during the production process, *e.g.*, from clonal selection of a cell line (*e.g.*, from a cell bank), to cell culture expansion, and final 25 production phase.

The method is performed by obtaining a sample comprising a polypeptide having a selected disulfide linkage pattern, for example, a multimeric polypeptide held together by one or more disulfide bonds or linkages, for example an antibody or half-antibody, and loading or contacting the sample with a separation medium or gel, for example a 30 organic polymer, which is confined to a opening or channel on a solid substrate, such as a chip. The separation medium or gel is then subjected to an electric field (*i.e.*, a current is applied to the gel) such that the polypeptide molecules migrate through the separation medium based on molecular weight. The migration of the polypeptide through the separation medium or gel being performed under conditions which preserve the disulfide 35 linkage pattern (or disulfide bonds) of the polypeptide (*e.g.*, non-reducing conditions). Accordingly, polypeptides having different disulfide linkage patterns can be distinguished, and in particular, multimeric polypeptides, such that tetrameric antibodies can be distinguished from heterodimeric half-antibodies.

In one embodiment, the actual detection of the migration pattern of the polypeptides having selected disulfide linkages is carried out using a dye (e.g., a fluorescent dye) which can interact with the polypeptide and be monitored visually, e.g., using a optical detection device (e.g., a fluorescence reader).

5        Conditions, reagent concentrations, detection dyes, and appropriate apparatus for conduction gel electrophoresis are well known in the art. Moreover, there exist numerous variations on the buffer conditions and detection reagents which may be adapted to the methods of the invention. Accordingly, the invention has the advantage of being conveniently incorporated into established protocols without the need for  
10      extensive re-optimization. In addition, the methods of the invention may be used for monitoring the nature of any polypeptide having a disulfide linkage.

In one particular embodiment, the methods of the invention are conducted, as noted above, using an Agilent 2100 Bioanalyzer together with the Protein 200 (or 200 Plus) LabChip Kit and the dedicated Protein 200 assay software which provides detailed  
15      data of the polypeptide size and concentration for up to 10 samples within 45 minutes. Software calculations are performed which provide the molecular weight (based on amount of fluorescence detected over time) for each polypeptide detected in the sample, relative polypeptide concentrations corresponding to each other polypeptide detected, and amount (percentage) of each polypeptide compared with the total relative  
20      polypeptide concentration in the sample. The method allows for an immediate determination of the amount (percentage) of half-antibody molecules in a given sample without the additional procedures necessary for conducting SDS-PAGE. The method also allows for the detection of impurities, e.g., polypeptide impurities.

The data presented in the examples below demonstrate the high precision of the  
25      method, particularly for determining the amount of completely formed antibodies relative to incompletely formed antibodies, *i.e.*, half-antibodies, as well as impurities. Moreover, the method of the invention using a chip-based gel electrophoresis approach is an illustration of the power of integrating multiple operations, on a chip, *e.g.*, staining, separating, and diluting protein samples, thereby providing a superior approach over  
30      conventional gel electrophoresis methods.

The invention also provides kits for the convenient practice of the methods of the invention. In one embodiment, the invention provides a kit for detecting the presence of a polypeptide having a selected disulfide linkage pattern comprising, a chip and instructions for carrying out the methods as described herein. The kit may also contain  
35      at least one other component such as separation medium, non-reducing buffer, protein dye, formulation buffer, and means for inducing an electric field through a separation medium.

In a preferred embodiment of the invention, any of the foregoing kits may be

further designed, packaged, or provided with instructions such that the kit may be conveniently used with a separation medium, non-reducing buffer, protein dye, chip and/or means for inducing an electric field through a separation medium, such as are available from, *e.g.*, Agilent Technologies (see, *e.g.*, U.S. Patent No. 6,254,754).

5 It is understood that other commercially available separation media (gels), detection agents (dyes), detectors, chips, and apparatuses for inducing an electric field, for carrying out the methods disclosed herein, are also encompassed by the invention (see, *e.g.*, U.S. Patent Nos. 6,176,990; 6,261,430; 5,750,015; 5,449,446; and 5,427,663).

10 The methods of the invention are applicable to a variety of uses including, bioproduction, research, diagnostic applications, and forensic science.

### ***Bioproduction***

15 The methods and kits of the invention have a variety of applications in the bioproduction of a polypeptide having a disulfide linkage. Indeed, antibodies (but also multimeric ligands) are a favored class of therapeutic polypeptides being commercially produced which are multimeric polypeptides linked by disulfide bonds.

20 Accordingly, the methods of the invention, as exemplified herein, are readily applied to the monitoring or quality control (QC) of any relevant stage of the bioproduction of a disulfide linked polypeptide, *e.g.*, clonal selection from a clone bank, cell culture expansion, and small and large scale production, *e.g.*, using biofermentors. Because the methods of the invention are rapid and can be automated, near real time analysis can be performed during production, and if desired, used to alter production parameters to influence the quality of production output.

### ***Research Applications***

25 The methods and kits of the invention have a variety of research applications. For example, they are useful for any research application in which an analysis must be performed rapidly or on limited amounts of a sample containing a polypeptide with a disulfide linkage, *e.g.*, a multimeric polypeptide, such as an antibody or ligand.

30 Other applications of the methods of the invention for research uses will be readily apparent to those skilled in the art.

### ***Diagnostic Applications***

35 The methods and kits of the invention are useful in a variety of diagnostic applications, such as the detection of inappropriate unlinked polypeptides (*e.g.*, half-antibodies) in a patient.

The methods and kits of the invention described herein may also be used to detect or characterize antibodies and/or half-antibodies associated with diseases, *e.g.*, genetic disorders or cellular disorders, such as cancer.

### 5 *Forensic Applications*

Forensic science is concerned with the scientific analysis of evidence from a crime. Forensic biology applies the experimental techniques of molecular biology, biochemistry, and genetics to the examination of biological evidence for the purpose, for example, of positively identifying the perpetrator of a crime. Typically, the sample size 10 of such biological evidence (*e.g.* blood) is small yet contains a sufficient amount of a polypeptide, for example, an antibody, capable of being detected according to the method of the invention.

Accordingly, the improved chip-based gel electrophoresis techniques of the invention may be used to detect polypeptides, *e.g.*, identifying antibodies, from even 15 small biological samples.

The following examples are included for purposes of illustration and should not be construed as limiting the invention.

### Exemplification

20 Throughout the examples, the following materials and methods were used unless otherwise stated.

### *Materials and Methods*

In general, the practice of the present invention employs, unless otherwise 25 indicated, conventional techniques of chemistry, molecular biology, recombinant DNA technology, immunology (especially, *e.g.*, immunoglobulin technology), and standard techniques in electrophoresis. See, *e.g.*, Sambrook, Fritsch and Maniatis, Molecular Cloning: Cold Spring Harbor Laboratory Press (1989); Antibody Engineering Protocols (Methods in Molecular Biology), 510, Paul, S., Humana Pr (1996); Antibody 30 Engineering: A Practical Approach (Practical Approach Series, 169), McCafferty, Ed., Irl Pr (1996); Antibodies: A Laboratory Manual, Harlow *et al.*, C.S.H.L. Press, Pub. (1999); Current Protocols in Molecular Biology, eds. Ausubel *et al.*, John Wiley & Sons (1992). Bousse *et al.*, Protein Sizing on a Microchip, *Anal. Chem.* 73, 1207-1212 (2001); Knapp *et al.*, Commercialized and Emerging Lab-on-a-Chip Applications; In: 35 *Proceedings of the μTAS 2001 Symposium*, Ramsey, J.M. & van den Berg, A., 7-10 (2001); and Mhatre *et al.*, Strategies for locating disulfide bonds in a monoclonal antibody via mass spectrometry, *Rapid Commun. Mass Spectrom.*, 13 (24) 2503-2510 (1999).

***Equipment and Samples***

Separation and detection of antibody samples was done using the Agilent 2100 Bioanalyzer instrument in combination with the Protein 200 (or 200 Plus) LabChip kit and the dedicated Protein 200 assay software. The Bioanalyzer uses epifluorescent

5 detection with a 10-mW semiconductor laser that emits at 630 nm. The instrument also contains 16 individually programmable high-voltage supplies.

**Table 1. Materials, Equipment, and Computer Systems:**

Item description	Manufacturer and Model #
Agilent 2100 Bioanalyzer	Agilent Technologies G2943AA
Agilent 2100 Bioanalyzer Software (revisions A.02.01 and A.02.11)	Agilent Technologies
Protein 200 (or 200 Plus) LabChip <sup>®</sup> Kit (reagents, 25 LabChips, 1 cleaning chip, 1 syringe and reagent kit guide)	Agilent Technologies (cat.# 5065-4430)
Chip Priming Station used to load gel matrix into chip.	Agilent Technologies (cat# 5065-4401)
Protein 200 Ladder and Upper Marker to use with the Protein 200 and 200+ LabChip Kit	Agilent Technologies (cat# 5065-4434)
Materials and Equipment to perform non-reducing SDS-PAGE	Standard Techniques
Densitometer and ImageQuant Software	Molecular Dynamics

10

***Sample Preparation***

Protein samples were diluted as needed using formulation buffer (e.g., PBS or 10 mM sodium phosphate, pH 6.0, 140 mM NaCl, 0.02% Tween-80KR) and denatured by mixing in a 2:1 ratio of denaturing buffer, and heated to 100°C for 5 min. Denaturing

15 buffer is provided with Agilent Protein 200 Assay kit and contains 4% SDS and 290 µg/ml myosin internal marker. Following denaturing, the samples for the experiments were diluted 1:15 in a 10% solution of lower marker dye from Agilent Technologies (excitation/emission wavelength 650/680 nm) in deionized water. Optimum protein concentration was determined to be 3000 µg/ml. Over ten different, representative

20 samples of an anti-integrin antibody produced recombinantly in NSO cells, using standard techniques, were used in the assays that follow.

***Chip Preparation (Chip Priming)***

For all separation experiments every channel in the glass chip was filled by

25 loading the sieving matrix into the right upper well labeled "G" and applying pressure for 1 min by following the standard procedure described in the Agilent Reagent kit guide (2000) (incorporated by reference). The sieving matrix used is a polymer based on polydimethylacrylamide at 3.25% in a Tris-Tricine buffer at pH 7.6 (120 mM Tricine, 42 mM Tris), containing 0.25% SDS (8.7 mM final concentration) and 4 µM of

30 the same dye used as a lower marker ("Agilent" dye). The sieving matrix is prepared

according to the standard procedure using the reagent provided in the kit. All four wells labeled "G" are filled with this solution. The SDS dilution well (labeled "DS") contains only the sieving matrix and the Tris-Tricine buffer. Protein samples (total volume 6 $\mu$ l) are applied to all remaining wells on the chip except the well next to G on the bottom.

5 This well (with the ladder mark) is filled with the protein ladder which includes 7 proteins with molecular weights from 14 to 210 kD.

#### *Data Capture and Analysis*

In the chip, electrophoresis moves each sample sequentially from its well to the central channel. As the samples move down the central channel they separate by size, finally passing the laser that excites the fluorescent dye bound to the sample. Data capture and analysis are performed with Agilent Technologies 2100 Bioanalyzer Software (revision A.02.01). The software analyzes data based on fluorescence intensity versus time. Quantitating the concentration and protein sizing are achieved by

10 comparing against a sizing ladder and internal standards ("markers") which are run with each sample. The data are presented as a gel-like image, an electropherogram, and in a tabular format (combined result table) which includes data on migration time, fluorescence intensity (as "Corr.area"), size, relative concentration, absolute concentration (option), and "% total".

15 The electropherogram from the Agilent 2100 Bioanalyzer visualizes the separation of the proteins according to their molecular weight (kD). The Protein 200 ladder is run on each chip from a designated ladder well. Following the analysis of the Protein 200 ladder, the software generates a calibration curve of the migration time versus the molecular weight of each protein in the ladder. This calibration curve is then

20 used to determine the size of each of the detected proteins in the 10 samples. The lower and upper markers, which are run with each of the 10 samples, correct for small drifts in migration time and ensure accurate sizing. The software automatically performs a sizing based on alignment with internal markers and an external protein standard. The determination of the molecular weight is based on the measured electrophoretic

25 migration time given in seconds.

The relative protein concentrations ( $\mu$ g/ml) were determined based on measuring peak areas and comparing them to the internal standard (the upper marker) of known protein concentration. The % Total is calculated based on the relative concentrations.

The results for each sample are viewed in real-time when detection is completed.

30 The first result is available in seven minutes with each subsequent analysis following in 2-minute intervals. The results are displayed in a tabular format, a gel-like image, and an electropherogram for each sample.

Each electropherogram contains a Lower Marker Peak, a System Peak and an Upper Marker Peak. The upper marker is 95% pure and contains two small impurities at 18 and 25 kD. The impurity level of the upper marker is corrected by the software for the concentration determination. Since these peaks are of the relatively low molecular 5 weights, they do not interfere with the antibody (or half-antibody) peaks.

### EXAMPLE 1

#### METHODS FOR DETERMINING, SIZING, ACCURACY AND REPRODUCIBILITY OF CHIP-BASED GEL ELECTROPHORESIS

10 Analysis of the anti-integrin antibody samples identified one major peak corresponding to completely formed anti-integrin antibody (MW ~160 kD), and a lower peak around ~ 89 kD corresponding to the half-antibody. The same peak pattern was found for different anti-integrin antibody samples also treated under non-reducing conditions. The molecular weights of these two peaks for different samples are shown 15 in Table 2, and the same data for anti-integrin antibody at different protein concentrations are shown in Figure 1. While the data are highly reproducible, the molecular weight of the major peak decreases as the sample concentrations increase from 50 to 4900  $\mu$ g/ml with an average MW of 161.1 for the intact anti-integrin antibody and 89.1 for the half-antibody

20

**Table 2. Sizing Accuracy of Chip-Based Method.**

Antibody Samples	Antibody MW (kD)	Half-antibody MW(kD)
1	156.3	88.9
2	154.7	89.3
12	161.1	90.8
5	157.4	90.1
6	156.5	90.8
3	157.9	90.8
4	157.9	90.8

### EXAMPLE 2

#### COMPARISON OF CHIP-BASED GEL ELECTROPHORESIS AND SDS-PAGE

25 The half-antibody in anti-integrin samples are detectable by a non-reducing SDS-PAGE as a band that migrates to 80 kD. Data obtained by conventional SDS-PAGE was compared with the data obtained by the chip-based method. SDS-PAGE under non-reducing conditions was performed according to standard techniques (e.g., 30 see Maniatis *et al.* (1995); Ausubel *et al.* (2001)). Typically for SDS-PAGE analysis under non-reducing conditions, usually 3  $\mu$ g protein samples are loaded on the gel. For the chip-based method, as little as 1  $\mu$ g is sufficient.

Subsequently, for some antibody samples, SDS-PAGE analysis was performed at the same low protein concentrations (or loaded amount of protein) as for the chip-based method in order to perform an accurate comparison (Table 3 and Figure 5). These chip-based results demonstrate a good correlation between the two methods. Data obtained 5 for a wide variety of antibody samples exhibiting a high percentage of half-antibodies, are presented in Table 3. For example, both SDS-PAGE and the chip-based method detected the high percentage of half-antibodies in the anti-integrin antibody samples 5, 8, 9 and 10 (Table 4). These results also demonstrate a good correlation between the two methods.

10

**Table 3. Comparison of the Data Obtained by Chip-Based Method and SDS-PAGE.**

Sample		% Half-antibody	
protein Id, ug	conc., ug/ml	chip-based	SDS-PAGE
1	3.8	11.7	10.8
0.8	3	10.7	10.2
0.6	2.3	11	9.3
0.5	1.9	10.8	8.6
0.4	1.5	10.1	13.5
0.3	1.1	9.3	8.6
0.2	0.8	9.8	10
0.1	0.4	11	6

15

Anti-integrin antibody sample 1 was analyzed at the different concentrations by the chip-based method (the percentage of half-antibodies was determined from the combined results table) and conventional SDS-PAGE.

**Table 4. Comparison of the Data Obtained by the Chip-Based Method and SDS-PAGE for Different Antibody Samples.**

Sample	Protein loaded, $\mu$ g			Half-Molecule, %
		chip-based	SDS-PAGE	
1	1	1	13.3	11.2
	0.5	0.5	10.9	9.3
	0.25	0.25	9.4	8.3
2	1	1	11.4	10.2
	0.5	0.5	10.9	9.2
	0.25	0.25	9	8.3
3	0.5	0.5	9.9	10.2
	0.25	0.25	8.3	10.7
4	0.5	0.5	10.3	12.7
	0.25	0.25	8.8	8.5
	1	3	17.1	17.4
5	0.5		17	
	0.25		15.3	
	0.12		14.2	
6	1	3	13.7	12.5
	0.5		12.9	
	0.25		12.6	
	0.12		9	
7	0.5	3	9.7	11.9
	0.27		8.4	
8	0.5	3	20.5	23.8
	0.27		19.1	
9	0.5	3	19	21.5
	0.27		18	
10	0.5	3	14.6	17.4
	0.27		14.2	
	0.5	3	11.7	11.7
	0.27		11.3	

5

Different antibody samples at the concentrations indicated were analyzed by the chip-based method and SDS-PAGE methods.

### EXAMPLE 3

#### 10 METHODS TO DETERMINE THE LINEAR DYNAMIC RANGE OF THE ASSAY

This example provides a method which can be used to determine the range of protein concentrations at which the results from this assay are accurate. To determine the linear dynamic range of the assay, anti-integrin antibody samples at concentrations 15 from 12.5 to 4900  $\mu$ g/ml were analyzed. Figure 2 (panels A-D) show the results of analysis of different anti-integrin antibody samples at the lowest concentrations (12.5, 50 and 100  $\mu$ g/ml) (B,C,D), and the control sample with the formulation buffer (A).

The peak corresponding to the half-antibody band could be detected only at the total sample concentration of 50  $\mu$ g/ml (C), although the intact antibody peak (MW ~ 171) can easily be seen at 12.5  $\mu$ g/ml (B). With the staining approach used for the chip-based method, it is to be expected that, at some relatively high concentrations of protein, 5 saturation in staining might be reached. An insufficient amount of dye might be present to bind in a quantitative fashion to the SDS-protein complexes. As a result the protein amount in the samples will be underestimated/overestimated. Accordingly it is important to identify the sample concentrations that give the linear correlation between the signal (the fluorescent intensity/relative concentration) and the "real" sample 10 concentration. "Real" sample concentrations were determined by standard procedure based on  $A_{280}$ . These data are presented as the total sample concentration, and the concentrations corresponding to antibody and half-antibody (~10%). Combined result table represents the different parameters of the assay results including fluorescence intensity (as 'Corr.area', relative concentration of the sample, and absolute 15 concentration of the sample).

Experiments demonstrate that there was a lower correlation between the real sample concentration and fluorescence intensity, so the "relative sample concentration" was tested. Relative protein concentrations ( $\mu$ g/ml) are obtained based on measuring peak areas and comparing these measurements against the upper marker (myosin), 20 which is used as an internal standard in each sample. The Agilent 2100 Bioanalyzer software automatically determines the peak area of the unknown proteins and the upper marker in each sample. The relative concentration of the unknown proteins within one sample is then calculated by the software based on the known concentration of the upper marker. The inclusion of the upper marker in each sample corrects for differences in 25 sample injection into the separation channel and allows for reproducible quantitation. Real sample concentration was compared ("X") to those determined by the software (relative and/or absolute) separately for the anti-integrin antibody and half-antibody. A sample of the reference standard (Sample 7) was diluted and tested as shown in Figures 3-6. The sample concentrations reported do not include the sample dilution by a factor 30 of 15 in water before the sample is loaded in the chip.

The assay is linear over two orders of magnitude, for example, from the lower detection limit, which is 12.5  $\mu$ g/ml, up to 2000  $\mu$ g/ml, based on the peak corresponding to the intact anti-integrin antibody (Figure 4). The linearity is slightly but gradually declines past 2000  $\mu$ g/ml (Figure 5). A correlation coefficient of  $R^2=0.98$  was 35 determined based on the intact antibody peak for the sample concentrations from 500 to 4900  $\mu$ g/ml. At the concentrations from 100 to 2000  $\mu$ g/ml,  $R^2=0.996$  was observed (Figure 4).

**EXAMPLE 4****METHODS FOR DETERMINING THE LINEAR DYNAMIC RANGE OF THE CHIP-BASED METHOD**

The following example provides a method by which the dynamic range of the 5 chip-based method can be determined. The anti-integrin antibody standard (Sample 7) was analyzed at the protein concentrations 100, 200, 500, 1000, 1500, 2000, 3000, 4000, and 4900  $\mu\text{g}/\text{ml}$ . Dilutions were made from the stock solution of the concentration 4900  $\mu\text{g}/\text{ml}$  (concentration was determined based on  $A_{280}$ ). The relative concentrations of the 10 peaks corresponding to the intact antibody peak (Figures 3 and 4) and the half-antibody peak (Figure 5 and 6) were determined for a range of protein concentrations based on the combined results table (provided by software; Table 4) and a robust linear dynamic range was observed.

**EXAMPLE 5****15 METHODS FOR DETERMINING THE CORRELATION BETWEEN THE DETERMINED ABSOLUTE AND RELATIVE ANTIBODY CONCENTRATIONS AND TOTAL ANTIBODY SAMPLE CONCENTRATIONS**

The following example provides a method by which the actual and relative 20 concentrations of a protein sample can be correlated. Two sets of antibody standards (sample 7) were analyzed at the following protein concentrations 1) 12.5, 25, 50, 100, 250, 500, 1000, 2000, and 4900  $\mu\text{g}/\text{ml}$  and 2) 100, 200, 500, 1000, 1500, 2000, 3000, 4000, and 4900  $\mu\text{g}/\text{ml}$ . Dilutions were made from a stock solution (4900  $\mu\text{g}/\text{ml}$ ; concentration was determined based on  $A_{280}$ ). Samples at all concentrations except 4900 25  $\mu\text{g}/\text{ml}$ , were used for the calibration curve for the absolute concentration determination. Total relative and absolute concentrations were determined from the combined results table.

The same graph based on the half-antibody peak demonstrates the linear 30 dynamic range for samples at the concentrations from 50 to 2000  $\mu\text{g}/\text{ml}$ . A correlation coefficient of  $R^2=0.949$  was determined for the sample concentrations from 100 to 4900  $\mu\text{g}/\text{ml}$  (Figure 5). At the concentrations from 100  $\mu\text{g}/\text{ml}$  to 2000  $\mu\text{g}/\text{ml}$  a correlation coefficient of  $R^2=0.987$  (Figure 6) was observed. Lower concentrations were not tested because the preliminary data already showed the absence of the half-antibody peak at 10-20  $\mu\text{g}/\text{ml}$ . Figure 7 demonstrates a good correlation between the relative and 35 absolute concentrations of samples determined by software analysis, and the real sample concentration determined based on  $A_{280}$  measurement. At low total sample concentrations, the % half-antibody (the relative concentration of the half-antibody) is

less than the % half-antibody obtained at the higher sample concentration (within a linear range).

#### EXAMPLE 6

#### 5      METHODS FOR DETERMINING THE OPTIMUM SAMPLE CONCENTRATION

The following example provides a method to determine the optimum protein concentration that should be used to obtain optimal results. To determine the optimum sample concentration, the results of % half-antibody obtained at different sample 10 concentrations were analyzed (Figure 8 and 9). The % half-antibody determined at lower concentrations are significantly lower ( $\leq$  1000  $\mu$ g/ml). Based on these results the recommended optimum sample concentration is 3000  $\mu$ g/ml.

#### EXAMPLE 7

#### 15     METHODS FOR DETERMINING OF THE LIMIT OF DETECTION (LOD)

The following example provides a method for determining the lowest concentration at which half-antibodies are accurately detected. The limit of detection was determined based on the observations that the lowest detected concentration for half-antibody is 2.7  $\mu$ g/ml at the sample concentration 50  $\mu$ g/ml. This determined 20 concentration resulted in the low % half-antibody detected (4.5 % compared with the average 10%, see below) thus, the real concentration of the half-antibody in the sample can be twice as much (~5  $\mu$ g/ml). Accordingly, the optimum sample concentration suggested for this assay is ~3000  $\mu$ g/ml. Based on this assumption, the limit of quantitation for the % half-antibody can be determined as the half-antibody 25 concentration of 5  $\mu$ g/ml (2 ng loaded), and 0.17% - (5  $\mu$ g/ml/3000 $\mu$ g/ml). As the % half-antibody is ~ 10%, it corresponds to a sample concentration of 50  $\mu$ g/ml.

The calculations were done based on relative concentration data. Figure 10 shows raw data at 50  $\mu$ g/ml. The half-antibody peak with a MW 89.66 is clearly distinguished from the background.

30

#### EXAMPLE 8

#### METHODS FOR DETERMINING THE LIMIT OF QUANTITATION (LOQ)

The following example provides a method by which the maximum concentration at which half-antibody determination is reliable. Specifically, to determine the limit of 35 quantitation, the % half-antibody determined at different sample concentrations were compared. The LOQ is determined to be a 613  $\mu$ g/ml sample concentration, and/or 1.9%. This was calculated based on the assumption that, the optimum sample concentration is 3000  $\mu$ g/ml and the average % half-antibody for the antibody reference

standard is 9.1%. Linear regression was applied for the points (sample concentrations) that gives the % half-antibody 20% higher or lower than the average (7.3 – 11 %).

### EXAMPLE 9

#### 5 METHODS FOR DETERMINING THE REPEATABILITY AND PRECISION OF THE CHIP-BASED METHOD

The following example provides a method to test the reproducibility and precision of the chip-based assay. The reproducibility of the assay was tested by using the same sample and the same chip, when using multiple chips, or when using the same 10 sample with different chips. The antibody reference standard (sample 7) was used to verify the repeatability of the chip-based method. Data obtained from running the same sample on the same chip are shown in Table 5. The data (the % half-antibody, which is “% Total” determined from the combined results table) are very similar with STDEV=0.5 and % STDEV=0.5 and 6.0, respectively, for antibody and half-antibody.

15

**Table 5. Comparison Data for Different Samples Run on the Same Chip**

	Antibody, %	Half-antibody, %
	90.6	9.4
	92.0	8.0
	92.3	7.7
	91.8	8.2
	91.8	8.2
	91.5	8.5
	91.4	8.6
	91.8	8.2
	91.2	8.8
	91.8	8.2
<b>Average</b>	<b>91.6</b>	<b>8.4</b>
<b>STDEV</b>	<b>0.5</b>	<b>0.5</b>
<b>%STDEV</b>	<b>0.5</b>	<b>6.0</b>

Data analysis of the same sample run on different chips are shown in Table 6.

20 The average for the % half-antibody determined at 0.1, 0.2, 0.3, 0.4 and 0.5  $\mu$ g is 9.5, with STDEV 0.3, and % STDEV 3.36.

**Table 6. Comparison Data for the Same Sample Run on Different Chips**

Load, $\mu$ g	0.5	0.4	0.3	0.2	0.1
Half-molecule, %	11.8	10.8	10	6.9	6.7
	11.5	11.5	10.7	7.2	7.1
	11.5	10.9	10.1	8.2	7.4
	11.4	11	10	7.6	7
	12	11	10.1	7.8	7
	12	11	10.2	7.6	6.8
Average	11.7	11	10.2	7.6	7
STDEV	0.3	0.2	0.3	0.5	0.2
%STDEV	2.6	1.8	2.9	6.6	2.9

5 An antibody sample (*i.e.*, number 12) was loaded in amounts of 0.1, 0.2, 0.3, 0.4 and 0.5  $\mu$ g (concentrations 370, 750, 1100, 1500 and 1870  $\mu$ g/ml) to determine the % half-antibody, and antibody. It was also observed that the assay can tolerate a large variety of sample buffers and additives.

10

## EXAMPLE 10

### METHODS FOR DETERMINING THE REPEATABILITY AND PRECISION OF THE CHIP-BASED METHOD FOR DETECTING IMPURITIES

15 The following example provides a method to test the reproducibility and precision of the chip-based assay for detecting impurities in a sample, for example, in a sample containing a recombinant antibody.

20 The reproducibility of the assay was tested by using several recombinant antibody samples having, for example, either known marker proteins of a certain concentration that were intentionally added, or, residual impurities from a standard recombinant protein preparation and recovery process that were detected by other means (*e.g.*, SDS-PAGE).

25 In one experiment, three marker proteins (trypsin inhibitor (MW 21 kD), ovalbumin (MW 46 kD), and galactosidase (MW 116 kD) were added to a recombinant antibody reference standard (*i.e.*, natalizumab) so that the final concentration of the sample was 4800  $\mu$ g/ml, and the final concentrations of the marker proteins were correspondent to 0.75%, 1%, 1.2%, and 1.5% impurity. The data of the recovery are shown in Table 7 and Fig. 12.

**Table 7. Recovery of Impurities in a Recombinant Protein Sample**

	Trypsin Inhibitor	Ovalbumin	Galactosidase
<b>Calculated % Impurity</b>	<b>0.75</b>	<b>0.75</b>	<b>0.75</b>
<b>Determined % Impurity Average (n=11)</b>	<b>0.8</b>	<b>0.3</b>	<b>0.8</b>
<b>STDEV</b>	<b>0.3</b>	<b>0.1</b>	<b>0.03</b>
<b>%STDEV</b>	<b>38</b>	<b>33</b>	<b>4</b>
<b>Calculated % Impurity</b>	<b>1</b>	<b>1</b>	<b>1</b>
<b>Determined % Impurity Average (n=11)</b>	<b>1</b>	<b>0.4</b>	<b>1.1</b>
<b>STDEV</b>	<b>0.4</b>	<b>0.1</b>	<b>0.1</b>
<b>%STDEV</b>	<b>40</b>	<b>25</b>	<b>9</b>
<b>Calculated % Impurity</b>	<b>1.2</b>	<b>1.2</b>	<b>1.2</b>
<b>Determined % Impurity Average (n=11)</b>	<b>0.39</b>	<b>0.34</b>	<b>1.3</b>
<b>STDEV</b>	<b>0.05</b>	<b>0.03</b>	<b>0.06</b>
<b>%STDEV</b>	<b>13</b>	<b>9</b>	<b>5</b>
<b>Calculated % Impurity</b>	<b>1.5</b>	<b>1.5</b>	<b>1.5</b>
<b>Determined % Impurity Average (n=11)</b>	<b>0.82</b>	<b>0.53</b>	<b>1.5</b>
<b>STDEV</b>	<b>0.27</b>	<b>0.08</b>	<b>0.21</b>
<b>%STDEV</b>	<b>33</b>	<b>15</b>	<b>14</b>

5 To determine the sensitivity of the chip-based method, a comparison of impurity analysis data obtained by SDS-PAGE and the chip-based method was performed (Figs. 13 and 14). A reducing SDS-PAGE indicated that the chip-based method had a limit of detection (LOD) of 0.1%, and limit of quantitation (LOQ) of 0.5%.

10 Accordingly, it was concluded that the chip-based method is an efficient and reliable approach for detecting and quantitating impurities in a polypeptide sample, *e.g.*, a sample containing a recombinant protein such as an antibody.

#### Equivalents


15 For one skilled in the art, using no more than routine experimentation, there are many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.





**Claims**


1. A method for detecting the presence of a IgG4 polypeptide having a selected disulfide linkage pattern in a sample comprising,
  - 5 loading a sample containing a polypeptide having a selected disulfide linkage pattern onto a chip comprising a channel having a separation medium effective to act as an obstacle to the migration of the polypeptide having a selected disulfide linkage pattern, and at least two electrodes disposed within the channel to induce an electric field,
  - 10 applying an electric field across the separation medium of the chip whereby a separation of the IgG4 polypeptide having a selected disulfide linkage pattern as compared to a IgG4 polypeptide not having the selected disulfide linkage pattern is achieved, and
    - 15 determining the presence of the IgG4 polypeptide having a selected disulfide linkage pattern.
2. A method for detecting the presence of a polypeptide having a selected disulfide linkage pattern in a sample consisting of a mixture of polypeptide multimers having two or more polypeptide chains and comprising at least one disulfide linkage between the polypeptide chains comprising,
  - 20 loading a sample containing the mixture of polypeptide multimers onto a chip comprising a channel having a separation medium effective to act as an obstacle to the migration of the polypeptide having a selected disulfide linkage pattern, and at least two electrodes disposed within the channel to induce an electric field,
  - 25 applying an electric field across the separation medium of the chip whereby a separation of the polypeptide having a selected disulfide linkage pattern as compared to a polypeptide not having the selected disulfide linkage pattern is achieved, and determining the presence of the polypeptide having a selected disulfide linkage pattern.
- 30 3. The method of claim 1 or 2, wherein the method further comprises determining the presence of a polypeptide impurity.
4. The method of claim 1, wherein the IgG4 polypeptide having a selected disulfide linkage pattern is a half-antibody.
- 35 5. The method of claim 2, wherein the polypeptide having a selected disulfide linkage is a half-antibody.


6. The method of claim 5, wherein the half-antibody is of the IgG4 class.
7. The method of claim 1, wherein the IgG4 polypeptide having a selected disulfide linkage pattern is recombinantly produced.  
5
8. The method of claim 1 or 2, wherein the polypeptide is recombinantly produced.
9. The method of claim 1 or 2, wherein the polypeptide having a selected disulfide linkage pattern is recombinantly produced.  
10
10. The method of claim 1, wherein, the IgG4 polypeptide not having the selected disulfide linkage pattern is an anti-integrin antibody.
11. The method of claim 2, wherein the mixture comprises an anti-integrin antibody.  
15
12. The method of claim 10 or 11, wherein the anti-integrin antibody is recombinantly produced.
13. The method of claim 1 or 2, wherein the sample is obtained from the growth medium of a cell culture.  
20
14. The method of claim 1 or 2, wherein the sample comprises about 1 to about 5000 ug/ml of a polypeptide having a selected disulfide linkage pattern.
- 25 15. The method of claim 1 or 2, wherein the separation medium is a gel polymer.
16. The method of claim 1 or 2, wherein the separation medium is non-reducing.
17. The method of claim 1 or 2, wherein the migration of the polypeptide is detected  
30 using a fluorescence detector.
18. The method of claim 1 or 2, wherein the electric field is non-alternating.
19. The method of claim 1 or 2, wherein the separation further comprises isoelectric  
35 focusing.
20. The method of claim 1 or 2, wherein the separation is according to the molecular weight of the polypeptide.


21. The method of claim 1 or 2, wherein the chip comprises a precast gel polymer.
22. A kit for detecting the presence of a polypeptide having a selected disulfide linkage pattern comprising, a chip and instructions for carrying out the method of claim 1.
23. A kit for determining the purity of a therapeutic polypeptide having a selected disulfide linkage pattern comprising, a chip and instructions for carrying out the method of claim 1.
24. The kit of claim 22 or 23, wherein the kit further comprises a component selected from the group consisting of, separation medium, non-reducing buffer, protein dye, formulation buffer, and means for inducing an electric field through a separation medium.
25. The kit of claim 22 or 23, wherein the kit further comprises instructions for determining the presence of a polypeptide impurity.
26. The kit of claim 22 or 23, wherein the kit further comprises one or more polypeptide standards.


**Fig. 1**


**Fig. 2****A. Formulation buffer.****B anti-integrin 12.5 µg/ml.****C anti-Integrin 50 µg/ml.****D. anti-integrin 100 µg/ml.**


**Fig. 3**


**Fig. 4**

**Fig. 5**

**Fig. 6**

**Fig. 7**

**Fig. 8**

**Fig. 9**





**Fig. 10**

Fig. 11

## Immunoglobulin Components



**Fig. 12**

**Fig. 13**

**Fig. 14**